Category: Health
The FDA has approved Guardant Health's Shield blood test as a primary screening tool for colon cancer in individuals aged 45 and older at average risk. The test shows 83% sensitivity for detecting colorectal cancer and meets Medicare coverage requirements. This approval is expected to enhance early detection and improve screening rates for colon cancer, which has a high survival rate when caught early.
Keywords: FDA approval, colon cancer, blood test
Update At: 7/30/2024